Elevation Oncology

Elevation Oncology is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients. By selectively developing drugs to inhibit specific alterations identified as disease drivers, it makes genomic testing actionable. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in tumor patients in the CRESTONE Phase 2 study.